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Background: The initial use of a 64-slice computed tomography (CT) scanner for obtaining 
quantitative perfusion data from a large ciliochoroidal melanoma, and correlation with 3T 
magnetic resonance imaging (MRI) dynamic enhancement and tumor histology.
Methods: The CT perfusion scan was performed using 80 kVp, 250 mA and 1-sec rotation 
time for 40 sec. The analysis was performed using commercial perfusion analysis software 
with a prototype 3-dimensional motion correction tool. Dynamic contrast-enhanced 3-Tesla 
MRI measured the kinetics of enhancement to estimate the vascular permeability. The time-
dependent enhancement patterns were obtained using the average signal intensity using Functool 
analysis software. The involved globe was enucleated and microscopic evaluation of the tumor 
was performed.
Results: The perfusion parameters blood ﬂ  ow, blood volume and permeability surface area 
product in the affected eye determined by CT perfusion analysis were 118 ml/100 ml/min, 
11.3 ml/100 ml and 48 ml/100 ml/min. Dynamic MRI enhancement showed maximal intensity 
increase of 111%. The neoplasm was a ciliochoroidal spindle cell melanoma which was mitoti-
cally active (13 mitoses/40 hpf). Vascular loops and arcades were present throughout the tumor. 
The patient developed metastases within 9 months of presentation.
Conclusion: Quantitative CT perfusion analysis of ocular tumors is feasible with motion 
correction software.
Keywords: ciliochoroidal melanoma, CT perfusion imaging, MR enhancement imaging, tumor 
blood volume, tumor blood ﬂ  ow, tumor permeability
Introduction
Choroidal melanomas have an incidence of 5–7 new cases per one million persons 
per year (Shields et al 1992; Singh et al 2003). They occur much more commonly in 
Caucasians than in African Americans (Egan et al 1988). There are no known risk 
factors other than a family history or ocular melanocytosis (Singh et al 1998).
In the eye, choroidal melanomas cause visual loss. Typical sites of metastases are 
the liver, the lung and rarely other organs (COMS Report No. 15 2001).
The risk factors for metastasis have traditionally been related to the size of the 
tumor and the cell type (McLean et al 1983; COMS Report No. 18 2001). Another 
and very important risk factor for metastasis is monosomy 3, although the mecha-
nism of how this is related to increased metastases is still not known (Prescher et al 
1996).
In addition, PAS positive loops are an independent risk factor for the development 
of metastasis (Rummelt et al 1995). These loops have been shown to be vascular loops 
made of a combination of endothelial cells and tumor cells. An increased number of 
vascular loops correlate with a worse prognosis.Clinical Ophthalmology 2008:2(2) 276
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Aside from the size and location, or cytogenic abnormality 
(monosomy 3 status) and gene expression proﬁ  ling informa-
tion derived from ﬁ  ne need aspiration, all of the other risk 
factors are usually known only at the time of the enucleation 
of the eye following examination of the specimen (Gunduz 
et al 1999; COMS Report No. 18 2001).
Since vascularity may be an important and independent 
indicator for prognosis, methods to determine the amount of 
vascularity short of removal of the eye are needed. Mueller 
and associates (2002) have attempted to look at the vascular-
ity by using indocyanine green (ICG). Buerk and colleagues 
(2004) have attempted to evaluate intratumoral vascularity 
with magnetic resonance imaging (MRI) by determining 
the relative enhancement over time. The problem with this 
technique is that it is only a relative technique and does 
not allow absolute quantitation. Additionally, the temporal 
sampling of the enhancing signal was only approximately 
40 seconds using the MRI dynamic enhancement protocol. 
We elected this approach to match the technique previously 
used by Buerk and colleagues (2004) to allow comparison 
of the computed tomography (CT) perfusion results with 
previously studied methods. It is important to note, however, 
MRI perfusion techniques can sample at 1–1.5 images per 
second, similar to CT.
Once metastasis occurs, the death rate is 80% at one 
year and 92% at two years (Bedikian et al 1995). Since the 
uveal melanomas express vascular endothelial growth factor 
(VEGF), which helps the tumor attract vessels to help nourish 
the tumor, attempts at the use of VEGF inhibitors are being 
considered as well (Lee et al 2006).
The use of CT to quantify vascular perfusion within 
tumors and organs has only recently been developed (Dugdale 
et al 1999; Seppenwoolde et al 2000; Fournier et al 2004; 
Kiessling et al 2004; Kan and Kobayashi et al 2005; Kan 
and Phongkitkarun et al 2005; Gandhi et al 2006; Laghi 
2006). The beneﬁ  ts of CT perfusion include the ability to 
measure absolute perfusion values and high temporal reso-
lution (measurements can be acquired every 1 sec, or less). 
Dependent on the acquisition protocol and analysis software 
various quantitative perfusion indices may be calculated. 
The goal of this study was to develop an in vivo measure of 
vascularity for patients presenting with choroidal melanomas, 
with the ultimate hope being that this will provide improved 
prognostic information without removal of the affected 
eye. We report for the ﬁ  rst time, in a patient with a large 
choroidal melanoma, the results of a 64-slice CT perfusion 
study and compare it to the relative enhancement from MRI 
and histopathologic ﬁ  ndings.
Materials and methods
Patient selection
A 50-year old patient presented with decreased vision in the 
right eye. Past medical and ocular history was unremark-
able. The visual acuity was 20/50 and 20/20 in the right 
and left eye respectively. The patient was noted to have a 
large pigmented ciliochoroidal melanoma with a base of 
19 × 16 mm. Standardized echography showed the presence 
of a low reﬂ  ective lesion with a thickness of 10.7 mm. 
Systemic evaluation including liver function tests, PET/CT 
scanning showed no evidence of detectable metastases. 
A diagnosis of large primary ciliochoroidal melanoma was 
made. Therapeutic alternatives were discussed and an enucle-
ation was chosen. The patient agreed to participate in a study 
protocol designed to evaluate the correlation of CT perfusion 
and MR enhancement indicators of tumor vascularity with 
histopathological ﬁ  ndings. Imaging was performed prior 
to surgical enucleation of the involved globe. This HIPPA 
compliant study was approved by our Institutional Review 
Board. At 9 months following initial presentation, the patient 
developed diffuse metastatic disease.
CT scan protocol
CT imaging was performed on a 64-slice CT scanner (Sensa-
tion 64, Siemens Medical Solutions, Forchheim, Germany). 
The patient was placed in the scanner bore in a head-ﬁ  rst 
position, lying on his side, with his head tilted comfortably 
toward the affected side to approximately 15°. This posi-
tion was used in order to keep the unaffected eye outside 
of the prescribed scan volume for the perfusion acquisition. 
Cushions and straps were placed to assist the patient in 
maintaining this position comfortably. To accurately verify 
patient radiation exposure, a thermoluminescent dosimeter 
(TLD) was placed on the surface of the closed eyelid of the 
unaffected eye and another placed adjacent to affected eye. 
A tissue-equivalent gel pad (SuperFlab, MedTec, Orange 
City, IA) was placed over the unaffected eye to help reduce 
the radiation to the lens of the unaffected eye.
A CT radiograph was acquired and used to center the scan 
volume over the affected eye while maximizing the distance 
to the unaffected eye. The superior ophthalmic artery and 
cavernous portion of the internal carotid artery ipsilateral to 
the affected eye were included in the scan ﬁ  eld. These vessels 
were used to measure the arterial input functions used for 
the perfusion calculations. The patient was coached to keep 
the affected (open) eye ﬁ  xed on one location, marked on the 
gantry in front of the patient’s head. This helped to minimize 
motion of the eyeball during the 40-second duration of the Clinical Ophthalmology 2008:2(2) 277
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perfusion scan, which could cause motion misregistration 
errors in the data analysis. Parameters for the perfusion 
scan included: scan ﬁ  eld-of-view (SFOV) = 50 cm, perfu-
sion scan mode (ie, no table increment between each scan), 
detector collimation = 24 × 1.2 mm, tube potential = 80 
kVp, tube-current time product = 250 mAs, reconstruction 
FOV 150 mm, 1 second tube rotation time for 40 seconds. 
The perfusion scan was initiated 3 sec after the start of the 
injection of 40 cc of iodinated contrast material (Omnipaque 
350, Amersham, Cork, Ireland), administered intravenously 
at 5 cc/sec, followed by an injection of an additional 30 cc of 
iodinated contrast material at 1 cc/sec and a 30 cc of saline 
injected at 1 cc/sec. Data was reconstructed using a 2.4 mm 
image widths for perfusion analysis. All raw data were saved 
for post-processing and perfusion analysis.
MRI dynamic enhancement technique
The MRI enhancement study was done using a similar 
technique to that described previously (Mueller et al 2002). 
MRI with intravenous contrast enhancement was performed 
on a 3.0 Tesla whole-body scanner (Signa VHi 3T; General 
Electric Medical Systems, Milwaukee, WI, USA). Sagittal 
T1-weighted FLAIR (ﬂ  uid attenuated inversion recovery) 
images (TR = 2,613 ms, TE = 16 ms, FOV = 24 cm2, acquisi-
tion matrix = 512 × 192, image thickness = 5 mm) through 
the head were used for graphic prescription of axial T2-
weighted fast-spin echo images (TR = 5,000 ms, TE = 102 ms,
FOV = 15 cm2, acquisition matrix = 416 × 416, image 
thickness = 1.5 mm, gap = 0.5 mm) through the orbits. Pre-
contrast axial T1-weighted spin echo images (TR = 400 ms, 
TE = 19 ms, FOV = 14 cm2, acquisition matrix = 416 × 160, 
image thickness = 3 mm, gap = 0.5 mm) were then obtained 
through the ocular lesion. For lesions placed in the superior 
or inferior regions of the globe, images were obtained in the 
coronal plane for improved visualization. Following intra-
venous administration of gadolinium contrast (Omniscan, 
0.1 mmol/kg) via an antecubital vein, ﬁ  ve axial T1-weighted 
spin echo sections were acquired through the globes at 1-
minute intervals for 7 minutes.
Histopathology
The patient’s eye was surgically enucleated. The speci-
men was ﬁ  xed for 48 hours in 10% buffered formalin and 
then gross examination was performed. The specimen 
was embedded in parafﬁ  n and sectioned at 4 μ. The sec-
tions were stained with hematoxylin-eosin and periodic 
acid/Schiff. The eye was examined by light microscopy 
for tumor location, cell type, mitotic index, presence of 
vascular loops and arcades and presence of extraocular 
extension.
Data analysis
A commercially available, FDA-approved CT perfusion 
software package (Neuro PCT, Siemens Medical Solu-
tions, Forchheim, Germany) was used for analysis of the 
CT perfusion data. In order to correct for some motion of 
the orbit during the scan acquisition, a prototype 3D regis-
tration tool was used to re-register the orbit to the original 
coordinates.
Perfusion images of the motion-corrected central 2.4 mm 
section were used to obtain quantitative measures of tumor 
blood ﬂ  ow, tumor blood volume and vascular permeability. 
The arterial input function was measured from an artery 
within the scan ﬁ  eld. Blood ﬂ  ow (F) (ml/100 ml tissue/min) 
was calculated using the maximum slope model (Miles et al 
1991; Klotz et al 1999), and blood volume (ml/100 ml tissue) 
(BV) and volume transfer coefﬁ  cient (Ktrans) (ml/100 ml 
tissue/min) using a modiﬁ  ed Patlak algorithm (Patlak et al 
1983; Dugdale et al 1999; Ng et al 2006). The volume 
transfer coefﬁ  cient Ktrans from the slope of the Patlak ﬁ  t 
describes the portion of whole blood ﬂ  ow that is extracted 
into extravascular space: Ktrans = E*F, with E the extraction 
fraction. This differs from Ktrans as it is now used in MRI, 
which is normalized to plasma ﬂ  ow by a factor of (1-Hct), 
with Hct being the hematocrit value. Permeability surface 
area product (PS) was calculated using the Renkin-Crone 
equation of capillary transport which provides a relation 
between E, F and PS: E = (1 − exp(-PS/F(1-Hct))) (Renkin 
1959; Crone 1963).
The MRI data was analyzed using the method previously 
described in detail (Mueller et al 2002). The time-dependent 
enhancement patterns were obtained using the average signal 
intensity from ﬁ  ve separate regions of interest placed over 
each of three locations: the ocular lesion, the brain gray 
matter, and the extraocular muscles, as a function of time 
(Functools; General Electric Medical Systems, Milwaukee, 
WI, USA). The average and standard deviation of the maxi-
mum enhancement for each region were calculated as the 
percentage difference between the pre-enhancement and 
maximum post-enhancement signal intensities divided by 
the pre-enhancement signal intensity for each tissue on the 
T1-weighted images (Microsoft Excel; Microsoft Corpora-
tion, Redmond, WA, USA). The gray matter of the brain 
served as a measure of signal intensity stability over time, 
because no enhancement should occur away from blood 
vessels when the blood-brain barrier is intact. The muscle Clinical Ophthalmology 2008:2(2) 278
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served as a measure of enhancement expected for normally 
perfused tissue.
Results
The results of the CT perfusion study were based on tumor 
voxel time-attenuation curves (TAC) such as the one shown in 
the lower half of Figure 1. TAC curves are readily measured 
with a CT scanner and reﬂ  ect the change in X-ray attenuation 
(CT number, HU) as the injected iodinated contrast material 
ﬂ  ows through the tumor. The corresponding Patlak analysis 
is shown in the upper half of Figure 1. The average perfusion 
parameters within the choroidal melanoma were determined 
by region of interest analysis (Figure 2). Blood ﬂ  ow was 118 
ml/100 ml/min, blood volume 11.3 ml/100 ml and Ktrans 
62 ml/100 ml/min. The resulting permeability surface area 
product was 48 ml/100 ml/min.
The MRI enhancement showed a maximum enhancement 
of 111% over baseline levels at 150 sec. The slope was 2.37 
MR enhancement units/sec (Figure 3a). There was a slow 
wash-out of 0.66 units/sec. There appeared to be a correlation 
between the areas of increased perfusion by CT and increased 
enhancement by MR (Figures 2, 3b).
Histology showed the presence of a large spindle cell 
melanoma with no sign of extraocular extension (Figures 
4a, 4b). The neoplasm was mitotically active (13 units/40 
hpf). Vascular loops and arches were present throughout the 
tumor. There was no tumor necrosis or tumor inﬁ  ltration of 
lymphocytes. The overlying retina was atrophic, and there 
was a localized exudative detachment.
Discussion
Present techniques for the diagnosis of choroidal melanoma 
do not allow determination of vascular ﬂ  ow. Considering 
that both brachytherapy and possibly anti-angiogenic therapy 
affect the vascularity of the tumor, it is important to develop 
methods that can determine the perfusion characteristics of 
choroidal melanomas.
Relative MRI enhancement and absolute CT perfusion 
imaging studies may allow the noninvasive evaluation 
of the vascularity of tumors. These techniques have been 
used to look at tumors in other organs (Seppenwoolde 
et al 2000; Fournier et al 2004; Laghi 2006). This is the 
ﬁ  rst study of CT perfusion studies in ocular tumors. One 
advantage of using CT compared to MRI is better spa-
tial resolution (0.29 × 0.29 × 2.4 mm3 voxel size for CT 
and 0.63 × 0.83 × 3.0 mm3 voxel size for MR). It would 
be very challenging from a technical standpoint to perform 
MRI enhancement studies of the orbit with such high spatial 
resolution. Furthermore, the temporal resolution of CT (we 
used 1 second intervals between measurements although this 
could be as short as 0.33 seconds) is superior to that of MRI 
perfusion techniques which has best temporal resolution of 
approximately 1 second. The potential drawback of using 
CT is that the patient is exposed to ionizing radiation, which 
has been shown to induce lens opacities at doses above 500 
mGy and cataracts at doses above 5000 mGy (International 
Commission on Radiological Protection 1991). For this 
study, we sought to minimize dose to the unaffected eye by 
tilting the head and using a superﬁ  cial absorber. With this 
technique, the dose to the surface of the unaffected eye was 
120 mGy, which is well below the thresholds for induction of 
lens opacities or cataracts. Thus, CT offers advantages over 
MRI in spatial and temporal resolution with negligible risk 
of radiation injury to the unaffected eye. Furthermore, the CT 
technique can provide absolute quantitative measurements 
of perfusion, whereas the MRI technique provides relative 
values that are not able to be compared between patients. This 
lack of an absolute measure limits the correlation of histology 
ﬁ  ndings to tumor perfusion for prognostic purposes.
It is important to note, however, that the dynamic MR 
enhancement technique used in this study gives different and 
complementary information about the tumor compared with 
the CT perfusion technique. The CT perfusion technique 
used in this study relies on intravascular indicator dilution 
analysis and two-compartment modeling, which may be 
used to characterize blood ﬂ  ow, blood volume and vascular 
permeability of the tumor. The MRI dynamic enhancement 
technique provides an estimate of the degree of endovascular 
permeability of the intrinsic tumor vascularity (Mueller et al 
2002). The clinical signiﬁ  cance of these measures of tumor 
vascularity remains to be further elucidated though interest-
ingly, in this patient, there was fast development of metastatic 
disease. One hypothesis would be that more rapidly growing 
tumors have higher vascular permeability than that of slower 
growing. Interestingly, in this case, there was close correla-
tion in the location and degree of increased perfusion in the 
tumor with the area of increased enhancement (permeability) 
(Figures 2, 3b).
This particular tumor had a marked number of small 
complex vessels forming loops and arcs by histological 
evaluation. CT perfusion studies have already been used as a 
predictive determinant of whether a lesion in the lung or liver 
is cancerous (Seppenwoolde et al 2000; Fournier et al 2004; 
Laghi 2006). It also has been used in patients before and after 
treatment to determine if there was a response to therapy. It 
also has been used to determine the effect of antiangiogenic Clinical Ophthalmology 2008:2(2) 279
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agents on tumor blood ﬂ  ow parameters. Considering that 
VEGF receptors have been noted on iris and choroidal 
melanomas, future studies to determine if chemotherapeutic 
agents including antiangiogenic therapies may have an effect 
on the tumors will require the use of diagnostic methods that 
help to determine the blood ﬂ  ow parameters to the lesion 
(Lee et al 2006). In addition, it may be an earlier determi-
nant of metastases since CT perfusion has been reported to 
have a high sensitivity in predicting malignancy of solitary 
pulmonary nodules and liver lesions (Kiessling et al 2004; 
Kan et al 2005). Furthermore, this technique has been shown 
to have a potential in assessing the grade, activity and treat-
ment response of lymphoma (Dugdale et al 1999). Perfusion 
values of liver metastases as measured with CT perfusion 
have been described to correlate with patient survival (Kan 
et al 2005), whereas in head-and-neck cancer, CT perfusion 
appeared to be an independent predictor of local outcome 
after irradiation (Gandhi et al 2006). Functional CT perfusion 
Figure 1 CT perfusion analysis is based on tumor voxel time-attenuation curves (TAC) such as the one shown in the lower half. Plotted is the CT-number (HU) as a function 
of time in seconds. For the voxel selected, the TAC starts at about 80 HU and increases by about 40 HU. The corresponding Patlak analysis is shown in the upper half. Plotted 
is the enhancement in the tumor voxel relative to the enhancement in the reference artery (c(t))/(b(t)) as a function of the so called Patlak time (Pt).
Figure 2 CT perfusion parameter images. Shown from left to right: Blood ﬂ  ow (118 ml/100 ml/min), blood volume (11.3 ml/100 ml) and Ktrans (62 ml/100 ml/min). 
Numbers are averaged over the displayed ROI. The color scale maps numbers from 0 to the number displayed above the scale.
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techniques have previously been successful in demonstrating 
decreasing effects of different angiogenesis inhibitors on 
tumor blood ﬂ  ow parameters (Kan and Kobayashi et al 2005; 
Kan and Phongkitkarun et al 2005; Wong et al 2006). The 
use of this technique before and after successful radiotherapy 
may add further data as to the validity of the thought that 
brachytherapy affects the tumor by ablating its vascularity 
(Kaiserman et al 2004). Future studies should be performed to 
compare perfusion with other available techniques, including 
monosomy 3 testing and ICG studies, as well as to determine 
the clinical value and cost-effectiveness of each technique.
In summary, we present the ﬁ  rst attempt at determining the 
perfusion characteristics of a large choroidal melanoma using 
state of the art 64-slice CT perfusion. We estimated tumor 
permeability using dynamic enhancement MRI. In addition, 
we show the relationship to histology of the tumor.
Figure 4a Low power photomicrograph of the tumor showing a predominance of 
cells forming fascicles and marked vascular channels. (Hematoxylin and eosin. X200).
A
Figure 4b High power photomicrograph showing several mitotic ﬁ  gures and the 
PAS positive vascular arcs and loops (Periodic acid Schiff X400).
Figure 3a Dynamic MRI enhancement. Relative MRI signal enhancement obtained 
from a region of interest placed within the choroidal melanoma (see ROI on image 
below) as a function of time (shown on x-axis in seconds). Following administration of 
gadolinium contrast via an antecubital vein, 7 volumes of same T1-weighted spin echo 
images were acquired through the globes at 1-minute intervals for 7 minutes. Data was 
analyzed on an independent computer workstation using Functool software.
Figure 3b MRI dynamic enhancement color overlay. The area under the dynamic 
enhancement curves was integrated on a pixel-by-pixel basis and overlayed onto its 
corresponding gadolinium enhanced axial T1-weighted image. Regions of the choroidal 
tumor which showed more enhancement over time are represented by the hotter 
colors. This dynamic enhancement is related to tumor permeability, and there is good 
correlation with CT perfusion results (see Figure 2).Clinical Ophthalmology 2008:2(2) 281
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